drugset / Trial / NCT04809116

Pimavanserin for Insomnia in Veterans With Posttraumatic Stress Disorder: Proof of Concept

NCT04809116

NaSingle-groupOpen-labelTreatment

Summary

This is a proof-of-concept, open-label trial of pimavanserin 34mg at bedtime for 6 weeks in Veterans with insomnia and Posttraumatic Stress Disorder.

Timeline

Start
2022-12-15
Primary completion
2023-12-15
Completion
2023-12-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Pimavanserin Small molecule 34 mg